A Phase 1/2A trial of idroxioleic acid: first-in-class sphingolipid regulator and glioma cell autophagy inducer with antitumor activity in refractory glioma [0.03%]
Idroxioleic酸：第一种鞘脂调节剂和胶质瘤细胞自噬诱导剂的1/2A期临床试验——用于治疗难治性胶质瘤的抗肿瘤活性研究
Juanita Lopez,Julia Lai-Kwon,Rhoda Molife et al.
Juanita Lopez et al.
Background: The first-in-class brain-penetrating synthetic hydroxylated lipid idroxioleic acid (2-OHOA; sodium 2-hydroxyoleate), activates sphingomyelin synthase expression and regulates membrane-lipid composition and mit...
PD-1 receptor outside the main paradigm: tumour-intrinsic role and clinical implications for checkpoint blockade [0.03%]
PD-1受体的非传统功能及其在肿瘤免疫检查点阻断治疗中的意义
C Donini,F Galvagno,R Rotolo et al.
C Donini et al.
Blocking the inhibitory receptor PD-1 on antitumour T lymphocytes is the main rationale underlying the clinical successes of cancer immunotherapies with checkpoint inhibitor (CI) antibodies (Abs). Besides this main paradigm, there is recent...
Nicardipine is a putative EED inhibitor and has high selectivity and potency against chemoresistant prostate cancer in preclinical models [0.03%]
尼卡地平是一种潜在的EED抑制剂，在临床前模型中针对耐化疗前列腺癌具有高选择性和效力
Xin Li,Yanhua Chen,Lijuan Bai et al.
Xin Li et al.
Background: It is imperative to develop novel therapeutics to overcome chemoresistance, a significant obstacle in the clinical management of prostate cancer (PCa) and other cancers. ...
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-expansion stage of a multicentre, open-label, phase I trial [0.03%]
帕米帕利联合泰斯罗利珠单抗治疗晚期实体瘤患者的疗效：一项多中心、开放标签1期剂量扩展试验结果
Michael Friedlander,Linda Mileshkin,Janine Lombard et al.
Michael Friedlander et al.
Background: The aim of this study was to investigate the antitumour activity, safety, and tolerability of pamiparib plus tislelizumab in patients with previously treated advanced solid tumours. ...
Diagnostic yield of a risk model versus faecal immunochemical test only: a randomised controlled trial in a colorectal cancer screening programme [0.03%]
风险模型与粪便免疫化学检测在结直肠癌筛查中的诊断效果：一项随机对照试验
Tim L Kortlever,Manon van der Vlugt,Floor A M Duijkers et al.
Tim L Kortlever et al.
Background: Combining the faecal immunochemical test (FIT) result with risk factors for advanced neoplasia (AN) may increase the yield of colorectal cancer (CRC) screening without increasing the number of colonoscopies. W...
Randomized Controlled Trial
British journal of cancer. 2023 Sep;129(5):791-796. DOI:10.1038/s41416-023-02358-z 2023
A real-world study of the first use of palbociclib for the treatment of advanced breast cancer within the UK National Health Service as part of the novel Ibrance® Patient Program [0.03%]
英国国家卫生服务局启动新型Ibrance®患者项目治疗晚期乳腺癌的真实世界研究
Carlo Palmieri,Alison Musson,Catherine Harper-Wynne et al.
Carlo Palmieri et al.
Background: The Ibrance® Patient Program was established to provide access to palbociclib for UK National Health Service (NHS) patients with metastatic breast cancer (MBC), pending a funding decision. ...
Exposure to benzene and other hydrocarbons and risk of bladder cancer among male offshore petroleum workers [0.03%]
海上石油工人接触苯及其他烃类物质与膀胱癌风险的关系
Nita K Shala,Jo S Stenehjem,Ronnie Babigumira et al.
Nita K Shala et al.
Background: Occupational exposures constitute the second leading cause of urinary bladder cancer after tobacco smoking. Increased risks have been found in the petroleum industry, but high-quality exposure data are needed ...
Chronic oxidative stress adaptation in head and neck cancer cells generates slow-cyclers with decreased tumour growth in vivo [0.03%]
慢性氧化应激适应使头颈部癌细胞成为生长减缓的细胞并在体内产生较小的肿瘤
Julia Berner,Lea Miebach,Marcel Kordt et al.
Julia Berner et al.
Background: Reactive oxygen species (ROS) are implicated in cancer therapy and as drivers of microenvironmental tumour cell adaptations. Medical gas plasma is a multi-ROS generating technology that has been shown effectiv...
Resistance to immune checkpoint therapies by tumour-induced T-cell desertification and exclusion: key mechanisms, prognostication and new therapeutic opportunities [0.03%]
肿瘤诱导的T细胞沙漠化和排挤引起的免疫检查点治疗抵抗：关键机制、预后及新的治疗机会
Mona Meng Wang,Sarah E Coupland,Tero Aittokallio et al.
Mona Meng Wang et al.
Immune checkpoint therapies (ICT) can reinvigorate the effector functions of anti-tumour T cells, improving cancer patient outcomes. Anti-tumour T cells are initially formed during their first contact (priming) with tumour antigens by antig...
The prognostic and biology of tumour-infiltrating lymphocytes in the immunotherapy of cancer [0.03%]
肿瘤浸润淋巴细胞在癌症免疫治疗中的预后和生物学特性
Yanbin Liu,Zhenjiang Liu,Yixiao Yang et al.
Yanbin Liu et al.
Tumour immunotherapy has achieved remarkable clinical success in many different types of cancer in the past two decades. The outcome of immune checkpoint inhibitors in cancer patients has been linked to the quality and magnitude of T cell, ...